{
  "id": "mhgap#risk_safety_9e6c9ce9",
  "content": "guideline stand alongside 90 pre-existing guideline\nquestions (ALC1, ALC2, ALC3, ALC4, CAMH1, STR1,\nrecommendations which were validated and continue\nSTR2, DRU1, DRU3, DRU4, EPI1, EPI2, OVE1, SUI3) were\nto be endorsed in their current format (7).\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\n3.1 Alcohol use disorders (ALC)\nALC1. In adults with alcohol dependence post-detoxification,\nis baclofen effective for relapse prevention and\nmanagement of alcohol dependence?\nRecommendation (update): Baclofen should be considered for treatment of adults with alcohol\ndependence post-detoxification.\nStrength of recommendation: Conditional\nCertainty of evidence: Moderate\nJustification y Post-detoxification refers to completion of the\ny A systematic review was updated: Agabio et al., 2023 management of withdrawal symptoms at least\n(17 RCTs) (25). three days before starting treatment. Most included\nstudies required participants to abstain from\ny Compared with placebo, baclofen decreases the\nalcohol for at least three days (3–28) before\nrisk of relapse into any drinking at end of treatment\nbeginning the pharmacological treatment.\n(high certainty) and increases the percentage of days\nabstinent at end of treatment (moderate certainty). y Service providers should include appropriate\npsychosocial interventions in their treatment plan\ny Compared with placebo, baclofen does not increase",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "risk_safety",
      "screening_cues",
      "referral",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Risk Safety guideline stand alongside 90 pre-existing guideline\nquestions (ALC1, ALC2, ALC3, ALC4, CAMH1, STR1,\nrecommendations which were validated and continue\nSTR2, DRU1, DRU3, DRU4, EPI1, EPI2, OVE1, SUI3) were\nto be endorsed in their current format (7).\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\n3.1 Alcohol use disorders (ALC)\nALC1. In adults with alcohol dependence post-detoxification,\nis baclofen effective for relapse prevention and\nmanagement of alcohol dependence?\nRecommendation (update): Baclofen should be considered for treatment of adults with alcohol\ndependence post-detoxification.\nStrength of recommendation: Conditional\nCertainty of evidence: Moderate\nJustification y Post-detoxification refers to completion of the\ny A systematic review was updated: Agabio et al., 2023 management of withdrawal symptoms at least\n(17 RCTs) (25). three days before starting treatment. Most included\nstudies required participants to abstain from\ny Compared with placebo, baclofen decreases the\nalcohol for at least three days (3–28) before\nrisk of relapse into any drinking at end of treatment\nbeginning the pharmacological treatment.\n(high certainty) and increases the percentage of days\nabstinent at end of treatment (moderate certainty). y Service providers should include appropriate\npsychosocial interventions in their treatment plan\ny Compared with placebo, baclofen does not increase Guideline stand alongside 90 pre-existing guideline\nquestions (alc1, alc2, alc3, alc4, camh1, str1,\nrecommendations which were validated and continue\nstr2, dru1, dru3, dru4, epi1, epi2, ove1, sui3) were\nto be endorsed in..."
}